Skip to main content
Erschienen in: PharmacoEconomics 4/2014

01.04.2014 | Current Opinion

Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room

verfasst von: Simon Eckermann, Brita Pekarsky

Erschienen in: PharmacoEconomics | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

In current literature, displaced services have been suggested to provide a basis for determining a threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed. We critically examine the conditions under which displaced services would represent an economically meaningful threshold value. We first show that if we assume that the least cost-effective services are displaced to finance a new technology, then the incremental cost-effectiveness ratio (ICER) of the displaced services (d) only coincides with that related to the opportunity cost of adopting that new technology, the ICER of the most cost-effective service in expansion (n), under highly restrictive conditions—namely, complete allocative efficiency in existing provision of health care interventions. More generally, reimbursement of new technology with a fixed budget comprises two actions; adoption and financing through displacement and the effect of reimbursement is the net effect of these two actions. In order for the reimbursement process to be a pathway to allocative efficiency within a fixed budget, the net effect of the strategy of reimbursement is compared with the most cost-effective alternative strategy for reimbursement: optimal reallocation, the health gain maximizing expansion of existing services financed by the health loss minimizing contraction. The shadow price of the health effects of a new technology, \( \beta_{c} = \left( {\frac{1}{n} + \frac{1}{d} - \frac{1}{m}} \right)^{ - 1} , \) accounts for both imperfect displacement (the ICER of the displaced service, d < m, the ICER of the least cost-effective of the existing services in contraction) and the allocative inefficiency (n < m) characteristic of health systems.
Fußnoten
1
One should note that health technology assessment has traditionally considered the average cost and effects of new technology measured incremental to a comparator. Using such average cost and effects in undertaking incremental analysis, there is an implicit assumption of constant returns to scale. However, more generally, in expanding or contracting current services, an appropriate consideration is at the margin.
 
Literatur
1.
Zurück zum Zitat Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
3.
Zurück zum Zitat Culyer AJ, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Ser Res Policy. 2007;12(1):56–8.CrossRef Culyer AJ, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Ser Res Policy. 2007;12(1):56–8.CrossRef
4.
Zurück zum Zitat McCabe C, Claxton K, Culyer AJ. The NICE cost effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–44.PubMedCrossRef McCabe C, Claxton K, Culyer AJ. The NICE cost effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–44.PubMedCrossRef
5.
Zurück zum Zitat Claxton K, Briggs A, Buxton M, McCabe C, Culyer A, Walker S, Sculpher M. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251–4.PubMedCentralPubMedCrossRef Claxton K, Briggs A, Buxton M, McCabe C, Culyer A, Walker S, Sculpher M. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251–4.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. J Health Ser Res Policy. 2008;13(Suppl 3):23–30.CrossRef Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. J Health Ser Res Policy. 2008;13(Suppl 3):23–30.CrossRef
7.
Zurück zum Zitat Sculpher M, Claxton K. Real economics needs to reflect real decisions. PharmacoEconomics. 2012;30(2):133–6.PubMedCrossRef Sculpher M, Claxton K. Real economics needs to reflect real decisions. PharmacoEconomics. 2012;30(2):133–6.PubMedCrossRef
8.
Zurück zum Zitat Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith P, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold: final report 2013. Working Paper 82. Centre for Health Economics, University of York; 2013. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith P, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold: final report 2013. Working Paper 82. Centre for Health Economics, University of York; 2013.
9.
Zurück zum Zitat Birch S, Gafni A. Cost effectiveness/utility analyses: do current decision rules lead us to where we want to be? J Health Econ. 1992;11:279–96.PubMedCrossRef Birch S, Gafni A. Cost effectiveness/utility analyses: do current decision rules lead us to where we want to be? J Health Econ. 1992;11:279–96.PubMedCrossRef
10.
Zurück zum Zitat Pekarsky B. Trusts, constraints and the counterfactual: reframing the political economy of new drugs. PhD Thesis, University of Adelaide; 2012. Pekarsky B. Trusts, constraints and the counterfactual: reframing the political economy of new drugs. PhD Thesis, University of Adelaide; 2012.
11.
Zurück zum Zitat Arrow K. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;5:941–67. Arrow K. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;5:941–67.
12.
Zurück zum Zitat Eckermann S, Karnon J, Willan A. The value of value of information: best informing research design and prioritization using current methods. PharmacoEconomics. 2010;28(9):699–709.PubMedCrossRef Eckermann S, Karnon J, Willan A. The value of value of information: best informing research design and prioritization using current methods. PharmacoEconomics. 2010;28(9):699–709.PubMedCrossRef
13.
Zurück zum Zitat Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195–209.PubMedCrossRef Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195–209.PubMedCrossRef
14.
Zurück zum Zitat Eckermann S, Willan AR. The option value of delay in health technology assessment. Med Decis Making. 2008;28:300–5.PubMedCrossRef Eckermann S, Willan AR. The option value of delay in health technology assessment. Med Decis Making. 2008;28:300–5.PubMedCrossRef
15.
Zurück zum Zitat Eckermann S, Willan AR. Time and EVSI wait for no patient. Val Health. 2008;11:522–6.CrossRef Eckermann S, Willan AR. Time and EVSI wait for no patient. Val Health. 2008;11:522–6.CrossRef
16.
Zurück zum Zitat Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ. 2009;18:203–16.PubMedCrossRef Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ. 2009;18:203–16.PubMedCrossRef
17.
Zurück zum Zitat Eckermann S, Willan A. Optimal global VOI trials: better aligning manufacturer and decision maker interest and enabling feasible risk sharing. PharmacoEconomics. 2013;31:393–401.PubMedCrossRef Eckermann S, Willan A. Optimal global VOI trials: better aligning manufacturer and decision maker interest and enabling feasible risk sharing. PharmacoEconomics. 2013;31:393–401.PubMedCrossRef
18.
Zurück zum Zitat Ruta D, Mitton C, Bate A, Donaldson C. Programme budgeting and marginal analysis: bridging the divide between doctors and managers. BMJ. 2005;330(25):1501–3.PubMedCentralPubMedCrossRef Ruta D, Mitton C, Bate A, Donaldson C. Programme budgeting and marginal analysis: bridging the divide between doctors and managers. BMJ. 2005;330(25):1501–3.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Ruta D, Donaldson C, Gilray L. Economics, public health and health care purchasing: the Tayside experience of programme budgeting and marginal analysis. J Health Serv Res Policy. 1996;1:185–93.PubMed Ruta D, Donaldson C, Gilray L. Economics, public health and health care purchasing: the Tayside experience of programme budgeting and marginal analysis. J Health Serv Res Policy. 1996;1:185–93.PubMed
20.
Zurück zum Zitat Mooney G, Coast J, Jan S, McIntyre D, Ryan M, Wiseman V. Not so nice…. J Health Ser Res Policy. 2008;12(3):190.CrossRef Mooney G, Coast J, Jan S, McIntyre D, Ryan M, Wiseman V. Not so nice…. J Health Ser Res Policy. 2008;12(3):190.CrossRef
21.
Zurück zum Zitat Willan AR, Eckermann S. Optimal clinical trial design using value of information with imperfect implementation. Health Econ. 2010;19:549–61.PubMed Willan AR, Eckermann S. Optimal clinical trial design using value of information with imperfect implementation. Health Econ. 2010;19:549–61.PubMed
22.
Zurück zum Zitat Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making. 2008;28:21–32.PubMedCrossRef Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making. 2008;28:21–32.PubMedCrossRef
23.
Zurück zum Zitat Willan AR, Eckermann S. Expected value of information and pricing new health care interventions. PharmacoEconomics. 2012;30(6):447–59.PubMedCrossRef Willan AR, Eckermann S. Expected value of information and pricing new health care interventions. PharmacoEconomics. 2012;30(6):447–59.PubMedCrossRef
24.
Zurück zum Zitat Eckermann S, Coelli T. Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice. Soc Sci Med. 2013;76:159–68.PubMedCrossRef Eckermann S, Coelli T. Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice. Soc Sci Med. 2013;76:159–68.PubMedCrossRef
26.
Zurück zum Zitat Karnon J, Caffrey O, Pham C, Grieve R, Ben-Tovim D, Hakendorf P, Crotty M. Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: estimating the costs and consequences of variation in clinical practice. Health Econ. 2013;22(6):631–42.PubMedCrossRef Karnon J, Caffrey O, Pham C, Grieve R, Ben-Tovim D, Hakendorf P, Crotty M. Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: estimating the costs and consequences of variation in clinical practice. Health Econ. 2013;22(6):631–42.PubMedCrossRef
27.
Zurück zum Zitat Eckermann S, Coory M, Willan A. Consistently estimating absolute risk difference when translating evidence to jurisdictions of interest. PharmacoEconomics. 2011;29(2):87–96.PubMedCrossRef Eckermann S, Coory M, Willan A. Consistently estimating absolute risk difference when translating evidence to jurisdictions of interest. PharmacoEconomics. 2011;29(2):87–96.PubMedCrossRef
28.
Zurück zum Zitat Weinstein M, Zeckerhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2:147–57.CrossRef Weinstein M, Zeckerhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2:147–57.CrossRef
Metadaten
Titel
Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room
verfasst von
Simon Eckermann
Brita Pekarsky
Publikationsdatum
01.04.2014
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 4/2014
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0140-3

Weitere Artikel der Ausgabe 4/2014

PharmacoEconomics 4/2014 Zur Ausgabe